Close Menu

NEW YORK – Invitae today announced a $50 million deal to acquire Jungla, an artificial intelligence-driven biotech firm that it believes will enhance its variant interpretation capabilities.

Jungla has developed the cloud-based Functional Modeling Platform, which uses machine learning to integrate functional, structural, and computational data and create predictive models that can be used to interpret the clinical significance of genomic variants. Invitae sees this technology as complementary to its own variant classification and interpretation method, called Sherloc.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Los Angeles brought and settled a civil enforcement action against the makers of an at-home test for SARS-CoV-2, NPR reports. 

The Guardian reports that Cancer Research UK is cutting its research funding by £44 million.

Technology Review examines factors affecting SARS-CoV-2 testing turnaround times.

In PNAS this week: mapping of ancient human migrations in Europe, recurrent gene fusion in breast cancer, and more.